Tackling influenza with broadly neutralizing antibodies

Corti, Davide; Cameroni, Elisabetta; Guarino, Barbara; Kallewaard, Nicole L.; Zhu, Qing; Lanzavecchia, Antonio

doi:10.1016/j.coviro.2017.03.002

Cited by 121 publications

(135 citation statements)

References 87 publications

Supporting

Mentioning

134

Contrasting

Order By: Relevance

“…150 Therefore passive immunization or postinfection treatment might soon become another tool to combat IFV. 125,126,151 HA-stalk and chimeric head/stalk-based vaccines have also shown encouraging preclinical results. 103,[152][153][154] A further vaccine strategy based on conserved epitopes in proteins, such as M1, NP, and PB1, involves induction of CD4 1 and CD8 1 T-cell immunity, 155 leading to development of a promising MVA viral vector vaccine.…”

Section: Vaccines and Mabsmentioning

confidence: 99%

Promising approaches for the treatment and prevention of viral respiratory illnesses

Papadopoulos

Megremis

Kitsioulis

et al. 2017

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Viral respiratory tract infections are the most common human ailments, leading to enormous health and economic burden. Hundreds of viral species and subtypes have been associated with these conditions, with influenza viruses, respiratory syncytial virus, and rhinoviruses being the most frequent and with the highest burden. When considering prevention or treatment of viral respiratory tract infections, potential targets include the causative pathogens themselves but also the immune response, disease transmission, or even just the symptoms. Strategies targeting all these aspects are developing concurrently, and several novel and promising approaches are emerging. In this perspective we overview the entire range of options and highlight some of the most promising approaches, including new antiviral agents, symptomatic or immunomodulatory drugs, the re-emergence of natural remedies, and vaccines and public health policies toward prevention. Wide-scale prevention through immunization appears to be within reach for respiratory syncytial virus and promising for influenza virus, whereas additional effort is needed in regard to rhinovirus, as well as other respiratory tract viruses.

show abstract

Section: Vaccines and Mabsmentioning

confidence: 99%

Promising approaches for the treatment and prevention of viral respiratory illnesses

Papadopoulos

Megremis

Kitsioulis

et al. 2017

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

show abstract

“…An alternative is the use of "broadly neutralizing antibodies (bNAb)", which are antibodies found in infected mammals able to neutralize most strains of a given highly antigenically variable pathogen. bNAbs have been isolated from infected humans against HIV [84], influenza [85], and dengue viruses [86]. Camelids could also be a source of bNAbs.…”

Section: Resultsmentioning

confidence: 99%

Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases

Lafaye

2018

Comparative Immunology, Microbiology and Infectious Diseases

View full text Add to dashboard Cite

A B S T R A C TCamelids produce both conventional heterotetrameric antibodies and homodimeric heavy-chain only antibodies. The antigen-binding region of such homodimeric heavy-chain only antibodies consists of one single domain, called VHH. VHHs provide many advantages over conventional full-sized antibodies and currently used antibody-based fragments (Fab, scFv), including high specificity, stability and solubility, and small size, allowing them to recognize unusual antigenic sites and deeply penetrate tissues. Since their discovery, VHHs have been used extensively in diagnostics and therapy. In recent decades, the number of outbreaks of diseases transmissible from animals to humans has been on the rise. In this review, we evaluate the status of VHHs as diagnostic and therapeutic biomolecular agents for the detection and treatment of zoonotic diseases, such as bacterial, parasitic, and viral zoonosis. VHHs show great adaptability to inhibit or neutralize pathogenic agents for the creation of multifunctional VHH-based diagnostic and therapeutic molecules against zoonotic diseases.

show abstract

“…Defining the G6 Idiotype on IGHV1-69-Encoded Human Anti-influenza Abs Targeting the HA Stem Domain We (Sui et al, 2009) and others (Corti et al, 2017;Pappas et al, 2014) discovered the biased use of IGHV1-69 F-alleles in HV1-69-sBnAbs. These data led us to further investigate if these HV1-69-sBnAbs also bind to the anti-Id + Ab G6.…”

Section: Resultsmentioning

confidence: 99%

Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-idiotypic Antibody G6 and Its Idiotope

Avnir¹,

Prachanronarong²,

Zhang³

et al. 2017

Cell Reports

View full text Add to dashboard Cite

The heavy chain IGHV1-69 germline gene exhibits a high level of polymorphism and shows biased use in protective antibody (Ab) responses to infections and vaccines. It is also highly expressed in several B cell malignancies and autoimmune diseases. G6 is an anti-idiotypic monoclonal Ab that selectively binds to IGHV1-69 heavy chain germline gene 51p1 alleles that have been implicated in these Ab responses and disease processes. Here, we determine the co-crystal structure of humanized G6 (hG6.3) in complex with anti-influenza hemagglutinin stem-directed broadly neutralizing Ab D80. The core of the hG6.3 idiotope is a continuous string of CDR-H2 residues starting with M53 and ending with N58. G6 binding studies demonstrate the remarkable breadth of binding to 51p1 IGHV1-69 Abs with diverse CDR-H3, light chain, and antigen binding specificities. These studies detail the broad expression of the G6 cross-reactive idiotype (CRI) that further define its potential role in precision medicine.

show abstract

Tackling influenza with broadly neutralizing antibodies

Cited by 121 publications

References 87 publications

Promising approaches for the treatment and prevention of viral respiratory illnesses

Promising approaches for the treatment and prevention of viral respiratory illnesses

Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases

Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-idiotypic Antibody G6 and Its Idiotope

Contact Info

Product

Resources

About